Product Images Alogliptin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Alogliptin NDC 71610-661 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Bottle Label 12.5 mg - 71610 0661 09
Aphena Pharma Solutions - TN - Aphena
Chemical Structure - alogliptin 01
Figure 1 - alogliptin 02
This text provides information on the use of Alogliptin in combination with several other drugs. It outlines the dosage, frequency, and duration of intake of Alogliptin with each drug, along with whether Alogliptin is a substrate for particular CYP enzymes or Pgp. However, there is no information on what Alogliptin is used for.*
Figure 2 - alogliptin 03
This text seems to describe a list of drugs with their dosages and administration schedules, as well as the effect of co-administration of other drugs on them. It also includes recommendations for dose adjustments based on the interaction of drugs with enzymes that metabolize them. Some of the drugs are metabolized by kidney (renally excreted), some by CYP2C8/9, CYP2C8, CYP2CS9, and CYP3A4 enzymes, and Pgp enzyme. There are no specific indications for these drugs, and the text doesn't provide any clinical context.*
Figure 3 - alogliptin 04
The text seems to describe the baseline mean A1C and its change in percentage for a study that compares the effects of Alogliptin, Pioglitazone, and their combination on type 2 diabetes patients. Different doses for both drugs are mentioned, but there is no clear information on their specific effects or results. The study used the last observation, and the changes in A1C are compared with a placebo group. There is a significant result indicated by P<0.001 for the combination treatment compared to the single-drug treatments.*
Figure 4 - alogliptin 05
This appears to be a table or chart with headings for "Placebo(P)", "NESINA(N)", and "Nversus P." There are columns containing data for "HR (98% CT)", "Atrisk", and the number of months from randomization. Without further context, it is not possible to provide a more detailed description.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
